Pyophage
AXP000244.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- Eliava Institute of Bacteriophage, Microbiology and Virology
- Sponsor
- Eliava Institute of Bacteriophage, Microbiology and Virology
Names
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- polyvalent bacteriophage cocktail (Pyo) against staphylococci, streptococci and enterococci, E. coli, Proteus mirabilis and P. aeruginosa
- Replication
- replicating
- Route
- intravesical
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42943970 | An Alternative Approach Against Resistent Infections: Long-Term Bacteriophage Therapy in Cystic Fibrosis. | Viruses | 2026 | name in abstract: Pyophage |
| PMID 40103254 | [Phage therapy analysis of effectiveness in comorbid patients with wounds and surgical infections of various etiology based on the results of a comparative clinical study]. | Khirurgiia | 2025 | name in abstract: Pyo bacteriophage |
| PMID 32949500 | Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. | The Lancet. Infectious diseases | 2021 | name in abstract: Pyo bacteriophage |
| PMID 30051571 | Metagenome analysis of Russian and Georgian Pyophage cocktails and a placebo-controlled safety trial of single phage versus phage cocktail in healthy Staphylococcus aureus carriers. | Environmental microbiology | 2018 | name in title: Pyophage |
| PMID 28950849 | Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. | BMC urology | 2017 | name in abstract: Pyo bacteriophage |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39994360 | Isolation and characterization of new lytic bacteriophage PSA-KC1 against Pseudomonas aeruginosa isolates from cystic fibrosis patients. | Scientific reports | 2025 | name in abstract: Pyophage |
| PMID 37325020 | Evaluation of the Lytic Activity of Various Phage Cocktails Against, ESBL-Producer, Non-Producer and Carbapenem-Resistant Escherichia coli Isolates. | Indian journal of microbiology | 2023 | name in abstract: Pyophage |
| PMID 35337865 | Bacteriophage cocktail as a promising bio-enhancer for methanogenic activities in anaerobic membrane bioreactors. | The Science of the total environment | 2022 | name in abstract: Pyophage |
| PMID 36561998 | Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era. | Acta pharmaceutica Sinica. B | 2022 | name in abstract: Pyo bacteriophage |
| PMID 36748697 | Development of an in vitro homeostasis model between airway epithelial cells, bacteria and bacteriophages: a time-lapsed observation of cell viability and inflammatory response. | The Journal of general virology | 2022 | name in abstract: Pyophage |
| PMID 34648883 | Growth characteristics of lytic cyanophages newly isolated from the Nakdong River, Korea. | Virus research | 2021 | name in abstract: Pyophage |
| PMID 32117136 | Antibacterial Efficacy of Two Commercially Available Bacteriophage Formulations, Staphylococcal Bacteriophage and PYO Bacteriophage, Against Methicillin-Resistant Staphylococcus aureus: Prevention and Eradication of Biofilm Formation and Control of a Systemic Infection of Galleria mellonella Larvae. | Frontiers in microbiology | 2020 | name in title: Pyo bacteriophage |
| PMID 32351494 | Using Bacteriophages as a Trojan Horse to the Killing of Dual-Species Biofilm Formed by Pseudomonas aeruginosa and Methicillin Resistant Staphylococcus aureus. | Frontiers in microbiology | 2020 | name in abstract: Pyophage |
| PMID 32889121 | Pyophage cocktail for the biocontrol of membrane fouling and its effect in aerobic microbial biofilm community during the treatment of antibiotics. | Bioresource technology | 2020 | name in title: Pyophage |
| PMID 30131795 | Adapted Bacteriophages for Treating Urinary Tract Infections. | Frontiers in microbiology | 2018 | name in abstract: Pyo bacteriophage |
| PMID 29099783 | Metagenomic Analysis of Therapeutic PYO Phage Cocktails from 1997 to 2014. | Viruses | 2017 | name in title: Pyophage |
| PMID 27148173 | Bacteriophages as Potential Treatment for Urinary Tract Infections. | Frontiers in microbiology | 2016 | name in abstract: Pyo bacteriophage |
| PMID 27175494 | [Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails]. | Mikrobiyoloji bulteni | 2016 | name in abstract: Pyophage |
| PMID 27857711 | In vitro Effectiveness of Commercial Bacteriophage Cocktails on Diverse Extended-Spectrum Beta-Lactamase Producing Escherichia coli Strains. | Frontiers in microbiology | 2016 | name in abstract: Pyo bacteriophage |
| PMID 30592832 | [Experience of the use of complex liquid pyo bacteriophage as a mean of prophylaxis of the acute tonsillitis in a military collective]. | Voenno-meditsinskii zhurnal | 2016 | name in title: Pyo bacteriophage |
| PMID 23637754 | The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. | PloS one | 2013 | name in abstract: Pyophage |
| PMID 8651825 | [Features of oral cavity microflora in congenital cleft lip and palate]. | Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] | 1995 | name in abstract: Pyophage |
Notes
Long-marketed Georgian polyvalent phage cocktail (Pyo bacteriophage). Tested against placebo and antibiotics in a randomised trial of urinary tract infection in men undergoing transurethral prostate resection (NCT03140085), where it was instilled into the bladder. The commercial cocktail's composition is adjusted over time, which the registry records as one program. The trial's protocol paper (Leitner 2017, BMC Urol 17:90, doi 10.1186/s12894-017-0283-6) lists the cocktail's five components as active against Enterococcus spp., E. coli, Proteus mirabilis, P. aeruginosa, Staphylococcus spp. and Streptococcus spp.
How to cite
Pyophage (AXP000244.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000244.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.